Disease Landscape and Forecast Insights

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just in the past year…

Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. Generic…

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…

Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or even aggression and can occur in both…

Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights…

TBI is a major cause of death and disability in the United States; DRG Epidemiology estimates that there were 250,000 moderate to severe TBI events diagnosed in U.S. hospitals / emergency rooms in…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…

MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin; it typically develops in early childhood and can persist into…

MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist…

The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of Sun Ophthalmics’ Cequa at a competitive…

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…